Cardiovascular comorbidities do not impact prostate artery embolisation (PAE) outcomes: retrospective analysis of the national UK-ROPE registry
Cardiovascular comorbidities do not impact prostate artery embolisation (PAE) outcomes: retrospective analysis of the national UK-ROPE registry
Purpose: Prostate artery embolisation (PAE) is a key treatment for the management of symptomatic benign prostatic hyperplasia (BPH). Common cardiovascular risk factors might be associated with suboptimal outcomes and thus influence patient treatment selection. The aim of the study was to evaluate whether cardiovascular comorbidities affect PAE outcomes. Methods: Retrospective subset analysis of the UK Registry of Prostate Artery Embolisation (UK-ROPE) database was performed with patients who had a full documented past medical histories including hypertension, diabetes, coronary artery disease (CAD), diabetes and smoking status as well as international prostate symptom score (IPSS) at baseline and at 12 months. Multiple regression was performed to assess for any significant predictors. Results: Comorbidity data were available for 100/216 patients (mean age 65.8 ± 6.4 years), baseline IPSS 20.9 ± 7.0). Regression analysis revealed that the presence of hypertension (53.7% IPSS reduction vs. absence 51.4%, p = 0.94), diabetes (52.6% vs. absence 52.1%, p = 0.6), CAD (59.2% vs. absence 51.4%, p = 0.95), no comorbidities (49.8% vs. any comorbidity present 55.3%, p = 0.66), smoking status (non-smoker, 52.6%, current smoker, 61.5%, ex-smoker, 49.8%, p > 0.05), age (p = 0.52) and baseline Qmax (p = 0.41) did not significantly impact IPSS reduction at 12 months post-PAE. Baseline prostate volume significantly influenced IPSS reduction (≥ 80 cc prostates, 58.9% vs. < 80 cc prostates 43.2%, p < 0.05). Conclusion: The presence of cardiovascular comorbidities/smoking history does not appear to significantly impact PAE symptom score outcomes at 12 months post procedure. Our findings suggest that if the prostatic artery can be accessed, then clinical success is comparable to those without cardiovascular comorbidities. Graphical Abstract: [Figure not available: see fulltext.]
Benign prostatic hyperplasia (BPH), Cardiovascular risk, Diabetes, Hypertension, Lower urinary tract symptoms (LUTS), Prostate artery embolisation (PAE), Smoking
115-120
Vigneswaran, Ganesh
4e3865ad-1a15-4a27-b810-55348e7baceb
Maclean, Drew
9a01537b-1471-4ea2-9273-23f4a86157b0
Doshi, Neel
a49ab1be-51b3-4e4c-b06a-7dc8e375cbac
Harris, Mark
065415f3-96a7-443c-91b4-f75a5945f82b
Bryant, Timothy J.C.
dc2d9494-0df6-4a42-a5ef-138ab8eb4e2a
Hacking, Nigel C.
08c6edc9-3fb3-4d09-a0ed-0efb4b0b93c1
Somani, Bhaskar
ab5fd1ce-02df-4b88-b25e-8ece396335d9
Modi, Sachin
1507f4a2-9733-4441-823a-666bb852e0f3
January 2024
Vigneswaran, Ganesh
4e3865ad-1a15-4a27-b810-55348e7baceb
Maclean, Drew
9a01537b-1471-4ea2-9273-23f4a86157b0
Doshi, Neel
a49ab1be-51b3-4e4c-b06a-7dc8e375cbac
Harris, Mark
065415f3-96a7-443c-91b4-f75a5945f82b
Bryant, Timothy J.C.
dc2d9494-0df6-4a42-a5ef-138ab8eb4e2a
Hacking, Nigel C.
08c6edc9-3fb3-4d09-a0ed-0efb4b0b93c1
Somani, Bhaskar
ab5fd1ce-02df-4b88-b25e-8ece396335d9
Modi, Sachin
1507f4a2-9733-4441-823a-666bb852e0f3
Vigneswaran, Ganesh, Maclean, Drew, Doshi, Neel, Harris, Mark, Bryant, Timothy J.C., Hacking, Nigel C., Somani, Bhaskar and Modi, Sachin
(2024)
Cardiovascular comorbidities do not impact prostate artery embolisation (PAE) outcomes: retrospective analysis of the national UK-ROPE registry.
Cardiovascular and Interventional Radiology, 47 (1), .
(doi:10.1007/s00270-023-03608-6).
Abstract
Purpose: Prostate artery embolisation (PAE) is a key treatment for the management of symptomatic benign prostatic hyperplasia (BPH). Common cardiovascular risk factors might be associated with suboptimal outcomes and thus influence patient treatment selection. The aim of the study was to evaluate whether cardiovascular comorbidities affect PAE outcomes. Methods: Retrospective subset analysis of the UK Registry of Prostate Artery Embolisation (UK-ROPE) database was performed with patients who had a full documented past medical histories including hypertension, diabetes, coronary artery disease (CAD), diabetes and smoking status as well as international prostate symptom score (IPSS) at baseline and at 12 months. Multiple regression was performed to assess for any significant predictors. Results: Comorbidity data were available for 100/216 patients (mean age 65.8 ± 6.4 years), baseline IPSS 20.9 ± 7.0). Regression analysis revealed that the presence of hypertension (53.7% IPSS reduction vs. absence 51.4%, p = 0.94), diabetes (52.6% vs. absence 52.1%, p = 0.6), CAD (59.2% vs. absence 51.4%, p = 0.95), no comorbidities (49.8% vs. any comorbidity present 55.3%, p = 0.66), smoking status (non-smoker, 52.6%, current smoker, 61.5%, ex-smoker, 49.8%, p > 0.05), age (p = 0.52) and baseline Qmax (p = 0.41) did not significantly impact IPSS reduction at 12 months post-PAE. Baseline prostate volume significantly influenced IPSS reduction (≥ 80 cc prostates, 58.9% vs. < 80 cc prostates 43.2%, p < 0.05). Conclusion: The presence of cardiovascular comorbidities/smoking history does not appear to significantly impact PAE symptom score outcomes at 12 months post procedure. Our findings suggest that if the prostatic artery can be accessed, then clinical success is comparable to those without cardiovascular comorbidities. Graphical Abstract: [Figure not available: see fulltext.]
Text
s00270-023-03608-6
- Version of Record
More information
Accepted/In Press date: 26 October 2023
e-pub ahead of print date: 27 November 2023
Published date: January 2024
Additional Information:
Publisher Copyright:
© 2023, The Author(s).
Keywords:
Benign prostatic hyperplasia (BPH), Cardiovascular risk, Diabetes, Hypertension, Lower urinary tract symptoms (LUTS), Prostate artery embolisation (PAE), Smoking
Identifiers
Local EPrints ID: 485581
URI: http://eprints.soton.ac.uk/id/eprint/485581
ISSN: 0174-1551
PURE UUID: d1cbdbc4-e918-4212-a1a2-8bd3af74c1cc
Catalogue record
Date deposited: 11 Dec 2023 17:35
Last modified: 18 Mar 2024 04:01
Export record
Altmetrics
Contributors
Author:
Drew Maclean
Author:
Neel Doshi
Author:
Mark Harris
Author:
Timothy J.C. Bryant
Author:
Nigel C. Hacking
Author:
Sachin Modi
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics